Recursion Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Recursion Pharmaceuticals's earnings have been declining at an average annual rate of -35.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 69.5% per year.
Key information
-35.1%
Earnings growth rate
31.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 69.5% |
| Return on equity | -70.8% |
| Net Margin | -736.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31
Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Recursion Pharmaceuticals: Destination Unknown
Sep 20Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth
Jul 25Recursion gets European orphan drug designation for its REC-4881 inhibitor
Jul 21These Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Sales Are Under Threat
May 16Recursion Pharmaceuticals, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 14Revenue & Expenses BreakdownBeta
How Recursion Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 45 | -328 | 111 | 241 |
| 30 Sep 23 | 47 | -293 | 102 | 0 |
| 30 Jun 23 | 50 | -260 | 92 | 0 |
| 31 Mar 23 | 47 | -249 | 82 | 0 |
| 31 Dec 22 | 40 | -239 | 82 | 156 |
| 30 Sep 22 | 29 | -247 | 78 | 0 |
| 30 Jun 22 | 18 | -234 | 74 | 0 |
| 31 Mar 22 | 13 | -212 | 70 | 0 |
| 31 Dec 21 | 10 | -186 | 58 | 135 |
| 30 Sep 21 | 10 | -147 | 46 | 0 |
| 30 Jun 21 | 9 | -124 | 37 | 0 |
| 31 Mar 21 | 6 | -99 | 29 | 0 |
| 31 Dec 20 | 4 | -87 | 25 | 0 |
| 31 Dec 19 | 2 | -62 | 19 | 0 |
Quality Earnings: RXRX is currently unprofitable.
Growing Profit Margin: RXRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RXRX is unprofitable, and losses have increased over the past 5 years at a rate of 35.1% per year.
Accelerating Growth: Unable to compare RXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RXRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: RXRX has a negative Return on Equity (-70.79%), as it is currently unprofitable.